Theravance Biopharma Q2 Adj $(0.13) Beats $(0.16) Estimate, Sales $13.75M Miss $15.24M Estimate
Portfolio Pulse from Benzinga Newsdesk
Theravance Biopharma reported Q2 losses of $0.28 per share, missing the analyst consensus estimate of $0.16 by 75%. This is a 600% increase in losses from the same period last year. The company also reported quarterly sales of $13.75 million, missing the analyst consensus estimate of $15.24 million by 9.78%. However, this is a 24.43% increase in sales from the same period last year.
August 07, 2023 | 8:39 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Theravance Biopharma's Q2 results missed analyst estimates, with a 75% larger loss than expected and sales falling short by 9.78%. Despite this, sales have increased by 24.43% compared to the same period last year.
The company's larger than expected losses and missed sales estimates are likely to negatively impact the stock price in the short term. However, the year-on-year increase in sales may provide some positive sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100